Nivolumab for Carcinoma

Phase-Based Progress Estimates
MD Anderson Cancer Center, Houston, TX
Carcinoma+2 More
Nivolumab - Drug
All Sexes
What conditions do you have?

Study Summary

To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).

Eligible Conditions

  • Carcinoma
  • Renal Medullary Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Carcinoma

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 2 year

Year 2
To establish the objective response rate (ORR) of patients with locally advanced or metastatic RMC treated with combination nivolumab plus relatlimab.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Carcinoma

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Nivolumab · No Placebo Group · Phase 2

Nivolumab+RelatlimabExperimental Group · 2 Interventions: Nivolumab, Relatlimab · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 2 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center 1Photo of MD Anderson Cancer Center 2Photo of MD Anderson Cancer Center 3
2004First Recorded Clinical Trial
74 TrialsResearching Carcinoma
520 CompletedClinical Trials

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,794,486 Total Patients Enrolled
256 Trials studying Carcinoma
37,368 Patients Enrolled for Carcinoma
Pavlos Msaouel, MD,PHD,PHDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients who have had prior nephrectomy are eligible.
There must be evidence of progression on or after last treatment regimen received.
You are unable to walk due to paralysis, but are mobile in a wheelchair.
You must be aged 18 years or older at the time of consent/assent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.